Inj Go-Cobal 85.00 Price Quantity * Add to Cart bottom of page
Additionally, it has been shown that BPC 157, even with a single administration, managed to control right heart failure, increased P wave amplitude, tachycardia, and ST elevation caused by acute thrombotic coronary occlusion in mice (6, 7, 8)
Baseline bloodwork CBC, CRP, ferritin, IL-6, cortisol AM, metabolic panel, thyroid function Cardiovascular assessment heart rate variability, orthostatic vitals if POTS is suspected Gut health markers stool testing, zonulin, calprotectin if GI symptoms are prominent Mitochondrial function proxies lactate, organic acids panel if PEM is a primary complaint From there, a typical protocol might be structured as: Phase 1 (Weeks 16): Immune and gut foundation Thymosin Alpha-1: 1.6 mg subcutaneous, twice weekly BPC-157: 250500 mcg daily, route determined by predominant symptom (oral for gut, injectable for systemic) Phase 2 (Weeks 412): Tissue repair and cardiovascular recovery TB-500: 2.02.5 mg subcutaneous, twice weekly Continue BPC-157 as indicated Phase 3 (Weeks 816): Maintenance and metabolic support Taper or pulse doses based on clinical response Add mitochondrial support if fatigue persists (see: Mitochondrial Peptides and Insulin Resistance) These are illustrative dosing ranges based on clinical research and published protocols
Olivia Svolgaard is an employee of Novo Nordisk A/S
But if you're metabolically healthy with no cardiac history and you're experiencing benign palpitations during dose escalation
Created to combat obesity and diabetes, GLP-1 agonists are now being assessed in dozens of disorders
